In this study, we aimed to evaluate CHI3L1 as a damage AKI biomarker and compare it with other damage biomarkers (NGAL, TIMP-2, IGFBP7, and NephroCheck®) in pediatric patients after CS. The gene discussed is TIMP2; the disease is acute kidney injury.